RegeneRx Biopharmaceuticals, Inc.
RGRX · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | -0% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 91.4% | 93.6% | 99.9% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $1 | $1 | $1 | $1 |
| SG&A Expenses | $1 | $1 | $1 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | -1,826.4% | -1,731.3% | -1,687.1% | -1,644% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | -$2 | -$2 | -$2 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$2 | -$2 | -$2 | -$1 |
| % Margin | -2,249.8% | -2,081.8% | -1,984.1% | -1,829% |
| EPS | -1 | -0.014 | -0.013 | -0.012 |
| % Growth | -7,094.2% | -6.1% | -10.1% | – |
| EPS Diluted | -1 | -0.014 | -0.013 | -0.012 |
| Weighted Avg Shares Out | 144 | 139 | 133 | 131 |
| Weighted Avg Shares Out Dil | 144 | 139 | 133 | 131 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $1 | $0 | $0 |
| EBITDA | -$1 | $0 | -$1 | -$1 |
| % Margin | -1,826.2% | 73% | -1,680% | -1,627.1% |